ClinVar Miner

Submissions for variant NM_003722.5(TP63):c.797G>A (p.Arg266Gln)

dbSNP: rs121908849
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000413620 SCV000490859 pathogenic not provided 2016-10-05 criteria provided, single submitter clinical testing The R266Q pathogenic variant in the TP63 gene, also referred to as R227Q due to the use of alternative nomenclature, is a common pathogenic variant that has been reported several times in association with Ectrodactyly-Ectodermal Dysplasia-Clefting (EEC) syndrome (van Bokhoven et al., 2001; Maclean et al., 2007; Sripathomsawat et al., 2011; Su et al., 2013). In vitro functional studies demonstrated that the R266Q variant enhances the transactivation of some TP63 targets and up-regulated the expression of mRNA and protein for TP63 target genes (Khokhar et al., 2008). The R266Q variant was not observed in approximately 6500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The R266Q variant is a semi-conservative amino acid substitution, and occurs at a position that is conserved across species. We interpret R266Q as a pathogenic variant.
Invitae RCV001390108 SCV001591730 pathogenic TP63-Related Spectrum Disorders 2022-08-07 criteria provided, single submitter clinical testing For these reasons, this variant has been classified as Pathogenic. Experimental studies are conflicting or provide insufficient evidence to determine the effect of this variant on TP63 function (PMID: 18626511). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C35"). ClinVar contains an entry for this variant (Variation ID: 6550). This variant is also known as R227Q. This missense change has been observed in individual(s) with TP63-related conditions (PMID: 11462173). It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 266 of the TP63 protein (p.Arg266Gln).
MGZ Medical Genetics Center RCV000006925 SCV002580717 likely pathogenic Ectrodactyly, ectodermal dysplasia, and cleft lip-palate syndrome 3 2022-04-04 criteria provided, single submitter clinical testing
OMIM RCV000006925 SCV000027121 pathogenic Ectrodactyly, ectodermal dysplasia, and cleft lip-palate syndrome 3 2011-01-01 no assertion criteria provided literature only
OMIM RCV000006926 SCV000027122 pathogenic ADULT syndrome 2011-01-01 no assertion criteria provided literature only
Bioscientia Institut fuer Medizinische Diagnostik GmbH, Sonic Healthcare RCV000006925 SCV000537817 pathogenic Ectrodactyly, ectodermal dysplasia, and cleft lip-palate syndrome 3 no assertion criteria provided clinical testing
Gharavi Laboratory, Columbia University RCV000413620 SCV000809433 pathogenic not provided 2018-09-16 no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.